Literature DB >> 23494844

2C or not 2C: phenethylamine designer drug review.

Be Vang Dean1, Samuel J Stellpflug, Aaron M Burnett, Kristin M Engebretsen.   

Abstract

New groups of synthetic "designer drugs" have increased in popularity over the past several years. These products mimic the euphoric effects of other well-known illicit drugs but are advertised as "legal" highs and are sold over the internet, at raves and night clubs, and in head shops. The 2C series drugs are ring-substituted phenethylamines that belong to a group of designer agents similar in structure to 3,4-methylenedioxy-N-methylamphetamine (MDMA, Ecstasy). Understanding the pharmacology and toxicology of these agents is essential in order to provide the best medical care for these patients. This review focuses on the pharmacology, pharmacokinetics, clinical effects, and treatment of 2C drug intoxication based on available published literature. Multiple names under which 2C drugs are sold were identified and tabulated. Common features identified in patients intoxicated with 2Cs included hallucinations, agitation, aggression, violence, dysphoria, hypertension, tachycardia, seizures, and hyperthermia. Patients may exhibit sympathomimetic symptoms or symptoms consistent with serotonin toxicity, but an excited delirium presentation seems to be consistent amongst deaths attributed to 2C drugs; at least five deaths have been reported in the literature in patients intoxicated with 2C drugs. 2C drugs are a group of designer intoxicants, many of which are marketed as legal, but may carry risks that consumers are unaware of. These drugs may be characterized by either serotonergic toxicity or a sympathomimetic toxidrome, but a presentation consistent with excited delirium is consistent amongst the reported 2C-related deaths. Treatment of 2C intoxication is primarily supportive, but immediate action is required in the context of excited delirium, hyperthermia, and seizure activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494844      PMCID: PMC3657019          DOI: 10.1007/s13181-013-0295-x

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  32 in total

Review 1.  Chemistry, pharmacology, and metabolism of emerging drugs of abuse.

Authors:  Hans H Maurer
Journal:  Ther Drug Monit       Date:  2010-10       Impact factor: 3.681

Review 2.  Metabolism of designer drugs of abuse: an updated review.

Authors:  Markus R Meyer; Hans H Maurer
Journal:  Curr Drug Metab       Date:  2010-06-01       Impact factor: 3.731

3.  New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques.

Authors:  Denis S Theobald; Michael Pütz; Erhard Schneider; Hans H Maurer
Journal:  J Mass Spectrom       Date:  2006-07       Impact factor: 1.982

Review 4.  New drugs of abuse in North America.

Authors:  Rachel Haroz; Michael I Greenberg
Journal:  Clin Lab Med       Date:  2006-03       Impact factor: 1.935

5.  Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series).

Authors:  Denis S Theobald; Hans H Maurer
Journal:  Biochem Pharmacol       Date:  2006-09-24       Impact factor: 5.858

Review 6.  Excited delirium syndrome (ExDS): treatment options and considerations.

Authors:  Gary M Vilke; William P Bozeman; Donald M Dawes; Gerard Demers; Michael P Wilson
Journal:  J Forensic Leg Med       Date:  2012-01-25       Impact factor: 1.614

7.  Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.

Authors:  J Battaglia; S Moss; J Rush; J Kang; R Mendoza; L Leedom; W Dubin; C McGlynn; L Goodman
Journal:  Am J Emerg Med       Date:  1997-07       Impact factor: 2.469

8.  Droperidol versus haloperidol for chemical restraint of agitated and combative patients.

Authors:  H Thomas; E Schwartz; R Petrilli
Journal:  Ann Emerg Med       Date:  1992-04       Impact factor: 5.721

9.  Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.

Authors:  A P Monte; D Marona-Lewicka; M A Parker; D B Wainscott; D L Nelson; D E Nichols
Journal:  J Med Chem       Date:  1996-07-19       Impact factor: 7.446

10.  A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients.

Authors:  Flavia Nobay; Barry C Simon; M Andrew Levitt; Graham M Dresden
Journal:  Acad Emerg Med       Date:  2004-07       Impact factor: 3.451

View more
  24 in total

1.  Electrical weapons and excited delirium: shocks, stress, and serum serotonin.

Authors:  Mark W Kroll; Stacey L Hail; Ryan M Kroll; Charles V Wetli; John C Criscione
Journal:  Forensic Sci Med Pathol       Date:  2018-08-11       Impact factor: 2.007

2.  Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication.

Authors:  Justin L Poklis; Carol R Nanco; Michelle M Troendle; Carl E Wolf; Alphonse Poklis
Journal:  Drug Test Anal       Date:  2013-09-02       Impact factor: 3.345

3.  Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper.

Authors:  Justin L Poklis; Stephen A Raso; Kylie N Alford; Alphonse Poklis; Michelle R Peace
Journal:  J Anal Toxicol       Date:  2015-10       Impact factor: 3.367

4.  New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents.

Authors:  Young-Jung Kim; Shi-Xun Ma; Kwang-Hyun Hur; Youyoung Lee; Yong-Hyun Ko; Bo-Ram Lee; Seon-Kyung Kim; Su-Jeong Sung; Kyeong-Man Kim; Hyoung-Chun Kim; Seok-Yong Lee; Choon-Gon Jang
Journal:  Arch Toxicol       Date:  2021-01-30       Impact factor: 5.153

5.  Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Authors:  Joshua S Elmore; Ann M Decker; Agnieszka Sulima; Kenner C Rice; John S Partilla; Bruce E Blough; Michael H Baumann
Journal:  Neuropharmacology       Date:  2018-03-01       Impact factor: 5.250

6.  C-N Cross-Coupling via Photoexcitation of Nickel-Amine Complexes.

Authors:  Chern-Hooi Lim; Max Kudisch; Bin Liu; Garret M Miyake
Journal:  J Am Chem Soc       Date:  2018-06-11       Impact factor: 15.419

7.  Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death.

Authors:  Justin L Poklis; Kelly G Devers; Elise F Arbefeville; Julia M Pearson; Eric Houston; Alphonse Poklis
Journal:  Forensic Sci Int       Date:  2013-10-18       Impact factor: 2.395

8.  2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.

Authors:  Samuel J Stellpflug; Samantha E Kealey; Cullen B Hegarty; Gregory C Janis
Journal:  J Med Toxicol       Date:  2014-03

9.  Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Authors:  Amy J Eshleman; Michael J Forster; Katherine M Wolfrum; Robert A Johnson; Aaron Janowsky; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2013-10-19       Impact factor: 4.530

10.  Stereoselective inhibition of serotonin transporters by antimalarial compounds.

Authors:  Matthew L Beckman; Akula Bala Pramod; Danielle Perley; L Keith Henry
Journal:  Neurochem Int       Date:  2013-10-23       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.